TTC1

Across TCGA pan-cancer cohorts, TTC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TTC1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC1 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and LUAD are the cancer types where TTC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.594	0.879	<.001	69	view →
LSCC	OS	Quartile	All	0.618	0.900	.011	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
GBM	OS	Median	All	0.266	0.524	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTC1–CCRCC (DFS)

Open the CCRCC breakdown →